Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Carly D MillerJohn R LozadaNicholas A ZorkoAndrew ElliottAllison MakovecMilan RadovichElisabeth I HeathArchana M AgarwalRana R McKayRohan GarjeBruno R BastosDave S B HoonJacob J OrmeA Oliver SartorAri M VanderWaldeChadi NabhanGeorge W SledgeEugene ShenderovScott M DehmEmil LouJeffrey S MillerJustin H HwangEmmanuel S AntonarakisPublished in: Cancer research communications (2024)
B7-H3-targeting therapeutics have shown promising results in initial clinical trials. In this pan-cancer analysis of B7-H3 mRNA expression, we found that B7-H3 exhibits robust expression in many common cancer types. These results may inform further development of B7-H3-targeting therapeutics and may guide clinical decisions for patients with limited treatment options.